Pfizer and Astellas Receive FDA Priority Review for Padcev
Pfizer (PFE) and Astellas (ALPMF, ALPMY) have received FDA priority review for their drug Padcev, which is an antibody drug conjugate. The approval is for the use of Padcev in combination with Merck’s drug. This development could have a positive impact on the stock prices of Pfizer and Astellas.
Topics: Astellas drug approval FDA Padcev Pfizer